Welcome to our dedicated page for Roche Holding news (Ticker: $RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.
Genentech, part of the Roche Group, reported positive Phase Ib results for its dual GLP-1/GIP receptor agonist, CT-388, in treating obesity.
Over 24 weeks, a weekly subcutaneous injection of CT-388 led to a significant placebo-adjusted weight loss of 18.8% (p < 0.001). Important results included 100% of treated participants achieving over 5% weight loss, 70% over 15%, and 45% over 20%. Additionally, pre-diabetic participants normalized their glycemia levels.
No new safety signals were detected. Adverse events were consistent with the incretin drug class. Further trials involving obese patients with type 2 diabetes are expected to report results in the second half of 2024.
Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in treating obesity and type 2 diabetes. Over 24 weeks, CT-388 achieved a significant placebo-adjusted weight loss of 18.8% (p < 0.001). At week 24, 100% of participants treated with CT-388 achieved >5% weight loss, 70% achieved >15%, and 45% achieved >20%. The treatment normalized glycemia in all pre-diabetic patients, showing strong glucose homeostasis impact. No new safety signals were detected, and the treatment was well-tolerated.
Looking forward, Roche plans to evaluate CT-388 in obese patients with type 2 diabetes over a 12-week treatment duration, with data expected in the second half of 2024.
Roche announced the FDA approval of its HPV self-collection solution, one of the first such options in the U.S. This tool improves access to HPV testing by allowing women to privately collect their own samples, which are then analyzed in a lab. The solution addresses a significant gap, as over half of U.S. cervical cancer patients are underscreened. Over 13,000 U.S. women are diagnosed with cervical cancer annually, and approximately 4,000 die from it. HPV self-collection could enable early detection and treatment, supporting the WHO's goal to eliminate cervical cancer by 2030. Roche collaborated with the National Cancer Institute for this initiative.